Happy 25th Anniversary p53 ! Since this is such a special occasion, I (GW) thought of explaining how fate brought p53 and me together. It was a snowy day in Utah when Arnie Levine came to the University of Utah in 1976 to present a lecture on genetic approaches to differentiation of teratocarcinoma cells. My graduate work with Mario Capecchi (starting at Harvard and continuing at the University of Utah) led me to appreciate the potential power of genetics in cancer research. I therefore arranged to visit Arnie’s lab to learn more about his research program. We discussed many topics, but not about how the large transforming protein (T antigen) of SV40 (SV40TAg) interacted with a putative ~54kDα cellular protein (Linzer and Levine, 1979).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alarcon, R., Koumenis, C., Geyer, R. K., Maki, C. G., and Giaccia, A. J. (1999). Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res 59, 6046-6051.
Alt, J. R., Greiner, T. C., Cleveland, J. L., and Eischen, C. M. (2003). Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J 22, 1442-1450.
Amundson, S. A., Patterson, A., Do, K. T., and Fornace, A. J., Jr. (2002). A nucleotide excision repair master-switch: p53 regulated coordinate induction of global genomic repair genes. Cancer Biol Ther 1, 145-149.
Appella, E., and Anderson, C. W. (2001). Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268, 2764-2772.
Argentini, M., Barboule, N., and Wasylyk, B. (2001). The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene 20, 1267-1275.
Ashcroft, M., Kubbutat, M. H., and Vousden, K. H. (1999). Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 19, 1751-1758.
Ashcroft, M., and Vousden, K. H. (1999). Regulation of p53 stability. Oncogene 18, 7637-7643.
Banin, S., Moyal, L., Shieh, S., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., and Ziv, Y. (1998). Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281, 1674-1677.
Barak, Y., Juven, T., Haffner, R., and Oren, M. (1993).mdm2 expression is induced by wild type p53 activity. Embo J 12, 461-468.
Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., and Berger, S. L. (2001). Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8, 1243-1254.
Bassing, C. H., and Alt, F. W. (2004). H2AX may function as an anchor to hold broken chromosomal DNA ends in close proximity. Cell Cycle 3, 149-153.
Bassing, C. H., Suh, H., Ferguson, D. O., Chua, K. F., Manis, J., Eckersdorff, M., Gleason, M., Bronson, R., Lee, C., and Alt, F. W. (2003). Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 114, 359-370.
Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., and Vousden, K.H. (1998). p14ARF links the tumour suppressors RB and p53. Nature 395, 124-125.
Bischoff, F. Z., Yim, S. O., Pathak, S., Grant, G., Siciliano, M. J., Giovanella, B. C., Strong, L. C., and Tainsky, M. A. (1990). Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res 50, 7979-7984.
Blattner, C., Tobiasch, E., Litfen, M., Rahmsdorf, H. J., and Herrlich, P. (1999). DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 18, 1723-1732.
Borges, H. L., Chao, C., Xu, Y., Linden, R., and Wang, J. Y. (2004). Radiation-induced apoptosis in developing mouse retina exhibits dose-dependent requirement for ATM phosphorylation of p53. Cell Death Differ 11, 494-502.
Bottger, A., Bottger, V., Sparks, A., Liu, W. L., Howard, S. F., and Lane, D. P. (1997). Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 7, 860-869.
Bottger, V., Bottger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., and Lane, D. P. (1999). Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18, 189-199.
Bottger, V., Bottger, A., Howard, S. F., Picksley, S. M., Chene, P., Garcia-Echeverria, C., Hochkeppel, H. K., and Lane, D. P. (1996). Identification of novel mdm2 binding peptides by phage display. Oncogene 13, 2141-2147.
Boyd, S. D., Tsai, K. Y., and Jacks, T. (2000). An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol 2, 563-568.
Brignone, C., Bradley, K. E., Kisselev, A. F., and Grossman, S. R. (2004). A postubiquitination role for MDM2 and hHR23A in the p53 degradation pathway. Oncogene.
Brodsky, M. H., Nordstrom, W., Tsang, G., Kwan, E., Rubin, G. M., and Abrams, J. M. (2000). Drosophila p53 binds a damage response element at the reaper locus. Cell 101, 103-113.
Brodsky, M. H., Weinert, B. T., Tsang, G., Rong, Y. S., McGinnis, N. M., Golic, K. G., Rio, D. C., and Rubin, G. M. (2004). Drosophila melanogaster MNK/Chk2 and p53 regulate multiple DNA repair and apoptotic pathways following DNA damage. Mol Cell Biol 24, 1219-1231.
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., and Vogelstein, B. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501.
Caelles, C., Helmberg, A., and Karin, M. (1994). p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370, 220-223.
Canman, C. E., Lim, D. S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., and Siliciano, J. D. (1998). Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281, 1677-1679.
Chao, C., Hergenhahn, M., Kaeser, M. D., Wu, Z., Saito, S., Iggo, R., Hollstein, M., Appella, E., and Xu, Y. (2003). Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem 278, 41028-41033.
Chao, C., Saito, S., Anderson, C. W., Appella, E., and Xu, Y. (2000a). Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. Proc Natl Acad Sci U S A 97, 11936-11941.
Chao, C., Saito, S., Kang, J., Anderson, C. W., Appella, E., and Xu, Y. (2000b). p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. Embo J 19, 4967-4975.
Chen, C. Y., Oliner, J. D., Zhan, Q., Fornace, A. J., Jr., Vogelstein, B., and Kastan, M. B. (1994). Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci U S A 91, 2684-2688.
Chen, J., Marechal, V., and Levine, A. J. (1993). Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13, 4107-4114.
Chin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S. L., Gottlieb, G. J., Greider, C. W., and DePinho, R. A. (1999). p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97, 527-538.
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., and Green, D. R. (2004). Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010-1014.
Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations [see comments]. Science 265, 346-355.
Craig, A. L., Burch, L., Vojtesek, B., Mikutowska, J., Thompson, A., and Hupp, T. R. (1999). Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem J 342, 133-141.
Cummings, J. M., Rago, C., Kohli, M., Kinzler, K. W., Lengauer, C., and Vogelstein, B.(2004). Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 428, 1 p following 486.
David-Pfeuty, T., Chakrani, F., Ory, K., and Nouvian-Dooghe, Y. (1996). Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumor cells and in untransformed cells. Cell Growth Differ 7, 1211-1225.
De Guzman, R. N., Liu, H. Y., Martinez-Yamout, M., Dyson, H. J., and Wright, P. E. (2000). Solution structure of the TAZ2 (CH3) domain of the transcriptional adaptor protein CBP. J Mol Biol 303, 243-253.
Deng, C., Zhang, P., Harper, J. W., Elledge, S. J., and Leder, P. (1995). Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684.
Denko, N. C., Giaccia, A. J., Stringer, J. R., and Stambrook, P. J. (1994). The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci U S A 91, 5124-5128.
Di Leonardo, A., Khan, S. H., Linke, S. P., Greco, V., Seidita, G., and Wahl, G. M. (1997). DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res 57, 1013-1019.
Dimri, G. P., Itahana, K., Acosta, M., and Campisi, J. (2000). Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol 20, 273-285.
Dornan, D., Wertz, I., Shimizu, H., Arnott, D., Frantz, G. D., Dowd, P., K, O. R., Koeppen, H., and Dixit, V. M. (2004). The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature.
Dumaz, N., and Meek, D. W. (1999). Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. Embo J 18, 7002-7010.
Dumaz, N., Milne, D. M., Jardine, L. J., and Meek, D. W. (2001). Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. Biochem J 359, 459-464.
Eischen, C. M., Roussel, M. F., Korsmeyer, S. J., and Cleveland, J. L. (2001). Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol 21, 7653-7662.
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., and Cleveland, J. L. (1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13, 2658-2669.
el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. (1992). Definition of a consensus binding site for p53. Nat Genet 1, 45-49.
el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
Espinosa, J. M., Verdun, R. E., and Emerson, B. M. (2003). p53 functions through stress-and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell 12, 1015-1027.
Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., and Weissman, A. M. (2000). Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275, 8945-8951.
Felsher, D. W., and Bishop, J. M. (1999). Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A 96, 3940-3944.
Fitch, M. E., Cross, I. V., Turner, S. J., Adimoolam, S., Lin, C. X., Williams, K. G., and Ford, J. M. (2003). The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. DNA Repair (Amst) 2, 819-826.
Freedman, D. A., and Levine, A. J. (1998). Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 18, 7288-7293.
Friedman, P. N., Chen, X., Bargonetti, J., and Prives, C. (1993). The p53 protein is an unusually shaped tetramer that binds directly to DNA [published erratum appears in Proc Natl Acad Sci U S A 1993 Jun 15;90(12):5878]. Proc Natl Acad Sci U S A 90, 3319-3323.
Fuchs, S. Y., Adler, V., Buschmann, T., Wu, X., and Ronai, Z. (1998). Mdm2 association with p53 targets its ubiquitination. Oncogene 17, 2543-2547.
Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E., and Shay, J. W. (1992). A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12, 2866-2871.
Gao, Y., Ferguson, D. O., Xie, W., Manis, J. P., Sekiguchi, J., Frank, K. M., Chaudhuri, J., Horner, J., DePinho, R. A., and Alt, F. W. (2000). Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature 404, 897-900.
Garcia-Echeverria, C., Chene, P., Blommers, M. J., and Furet, P. (2000). Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J Med Chem 43, 3205-3208.
Geyer, R. K., Yu, Z. K., and Maki, C. G. (2000). The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2, 569-573.
Gorina, S., and Pavletich, N. P. (1996). Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2 [see comments]. Science 274, 1001-1005.
Gorlich, D., and Kutay, U. (1999). Transport between the cell nucleus and the cytoplasm. Annu Rev Cell Dev Biol 15, 607-660.
Gottlieb, T. M., Leal, J. F., Seger, R., Taya, Y., and Oren, M. (2002). Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 21, 1299-1303.
Grossman, S. R., Deato, M. E., Brignone, C., Chan, H. M., Kung, A. L., Tagami, H., Nakatani, Y., and Livingston, D. M. (2003). Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300, 342-344.
Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z. X., Kumar, S., Howley, P. M., and Livingston, D. M. (1998). p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 2, 405-415.
Gu, J., Kawai, H., Nie, L., Kitao, H., Wiederschain, D., Jochemsen, A. G., Parant, J., Lozano, G., and Yuan, Z. M. (2002). Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem 277, 19251-19254.
Gu, W., and Roeder, R. G. (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606.
Gu, W., Shi, X. L., and Roeder, R. G. (1997). Synergistic activation of transcription by CBP and p53. Nature 387, 819-823.
Hainaut, P., Hall, A., and Milner, J. (1994). Analysis of p53 quaternary structure in relation to sequence-specific DNA binding. Oncogene 9, 299-303.
Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
Hay, T. J., and Meek, D. W. (2000). Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. FEBS Lett 478, 183-186.
Henderson, B. R., and Eleftheriou, A. (2000). A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals. Exp Cell Res 256, 213-224.
Hermeking, H., Lengauer, C., Polyak, K., He, T. C., Zhang, L., Thiagalingam, S., Kinzler, K.W., and Vogelstein, B.(1997).14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1, 3-11.
Hicke, L. (2001). Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2, 195-201.
Hiyama, H., Yokoi, M., Masutani, C., Sugasawa, K., Maekawa, T., Tanaka, K., Hoeijmakers, J. H., and Hanaoka, F. (1999). Interaction of hHR23 with S5a. The ubiquitin-like domain of hHR23 mediates interaction with S5a subunit of 26 S proteasome. J Biol Chem 274, 28019-28025.
Hollander, M. C., Sheikh, M. S., Bulavin, D. V., Lundgren, K., Augeri-Henmueller, L., Shehee, R., Molinaro, T. A., Kim, K. E., Tolosa, E., Ashwell, J. D., et al. (1999). Genomic instability in Gadd45a-deficient mice. Nat Genet 23, 176-184.
Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. (1991). p53 mutations in human cancers. Science 253, 49-53.
Honda, R., Tanaka, H., and Yasuda, H. (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420, 25-27.
Honda, R., and Yasuda, H. (1999). Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. Embo J 18, 22-27.
Honda, R., and Yasuda, H. (2000). Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19, 1473-1476.
Huang, L. C., Clarkin, K. C., and Wahl, G. M. (1996). Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci U S A 93, 4827-4832.
Hwang, B. J., Ford, J. M., Hanawalt, P. C., and Chu, G. (1999). Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci U S A 96, 424-428.
Inga, A., Storici, F., Darden, T. A., and Resnick, M. A. (2002). Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 22, 8612-8625.
Inoue, T., Geyer, R. K., Howard, D., Yu, Z. K., and Maki, C. G. (2001). MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J Biol Chem 276, 45255-45260.
Jabbur, J. R., Tabor, A. D., Cheng, X., Wang, H., Uesugi, M., Lozano, G., and Zhang, W. (2002). Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene 21, 7100-7113.
Jackson, M. W., and Berberich, S. J. (2000). MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol 20, 1001-1007.
Janus, F., Albrechtsen, N., Dornreiter, I., Wiesmuller, L., Grosse, F., and Deppert, W. (1999). The dual role model for p53 in maintaining genomic integrity. Cell Mol Life Sci 55, 12-27.
Jeffers, J. R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J., MacLean, K. H., Han, J., Chittenden, T., Ihle, J. N., et al. (2003). Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4, 321-328.
Jimenez, G. S., Khan, S. H., Stommel, J. M., and Wahl, G. M. (1999). p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 18, 7656-7665.
Jimenez, G. S., Nister, M., Stommel, J. M., Beeche, M., Barcarse, E. A., Zhang, X. Q., O'Gorman, S., and Wahl, G. M. (2000). A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nat Genet 26, 37-43.
Jin, S., Antinore, M. J., Lung, F. D., Dong, X., Zhao, H., Fan, F., Colchagie, A. B., Blanck, P., Roller, P. P., Fornace, A. J., Jr., and Zhan, Q. (2000). The GADD45 inhibition of Cdc2 kinase correlates with GADD45-mediated growth suppression. J Biol Chem 275, 16602-16608.
Jones, S. N., Roe, A. E., Donehower, L. A., and Bradley, A. (1995). Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208.
Joseph, T. W., Zaika, A., and Moll, U. M. (2003). Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage. Faseb J 17, 1622-1630.
Kamijo, T., Bodner, S., van de Kamp, E., Randle, D. H., and Sherr, C. J. (1999a). Tumor spectrum in ARF-deficient mice. Cancer Res 59, 2217-2222.
Kamijo, T., van de Kamp, E., Chong, M. J., Zindy, F., Diehl, J. A., Sherr, C. J., and McKinnon, P. J. (1999b). Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. Cancer Res 59, 2464-2469.
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. (1998). Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 95, 8292-8297.
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., and Sherr, C. J. (1997). Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659.
Kane, S. A., Fleener, C. A., Zhang, Y. S., Davis, L. J., Musselman, A. L., and Huang, P. S. (2000). Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence. Anal Biochem 278, 29-38.
Karlseder, J., Broccoli, D., Dai, Y., Hardy, S., and de Lange, T.(1999). p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283, 1321-1325.
Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51, 6304-6311.
Kastan, M. B., Zhan, Q., el-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597.
Kawai, H., Wiederschain, D., Kitao, H., Stuart, J., Tsai, K. K., and Yuan, Z. M. (2003a). DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem 278, 45946-45953.
Kawai, H., Wiederschain, D., and Yuan, Z. M. (2003b). Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 23, 4939-4947.
Khan, S. H., Moritsugu, J., and Wahl, G. M. (2000). Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc Natl Acad Sci U S A 97, 3266-3271.
Khan, S. H., andWahl, G. M. (1998). p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res 58, 396-401.
Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shiloh, Y., and Shkedy, D. (1999). Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A 96, 14973-14977.
Kobet, E., Zeng, X., Zhu, Y., Keller, D., and Lu, H. (2000). MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci U S A 97, 12547-12552.
Kubbutat, M. H., Jones, S. N., and Vousden, K. H. (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303.
Kudo, N., Wolff, B., Sekimoto, T., Schreiner, E. P., Yoneda, Y., Yanagida, M., Horinouchi, S., and Yoshida, M. (1998). Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp Cell Res 242, 540-547.
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., and Pavletich, N. P. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953.
Lai, Z., Ferry, K. V., Diamond, M. A., Wee, K. E., Kim, Y. B., Ma, J., Yang, T., Benfield, P.A., Copeland, R. A., and Auger, K. R. (2001). Human mdm2 mediates multiple monoubiquitination of p53 by a mechanism requiring enzyme isomerization. J Biol Chem 276, 31357-31367.
Lambert, P. F., Kashanchi, F., Radonovich, M. F., Shiekhattar, R., and Brady, J. N. (1998). Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem 273, 33048-33053.
Lane, D. P. (1992). Cancer. p53, guardian of the genome. Nature 358, 15-16.
Lane, D. P., and Crawford, L. V. (1979). T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261-263.
Langheinrich, U., Hennen, E., Stott, G., and Vacun, G. (2002). Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling. Curr Biol 12, 2023-2028.
Lanni, J. S., and Jacks, T. (1998). Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18, 1055-1064.
Lee, J. H., Lee, E., Park, J., Kim, E., Kim, J., and Chung, J. (2003). In vivo p53 function is indispensable for DNA damage-induced apoptotic signaling in Drosophila. FEBS Lett 550, 5-10.
Lees-Miller, S. P., and Meek, K. (2003). Repair of DNA double strand breaks by non-homologous end joining. Biochimie 85, 1161-1173.
Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., and Benchimol, S. (2003). Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112, 779-791.
Lev Bar-Or, R., Maya, R., Segel, L. A., Alon, U., Levine, A. J., and Oren, M. (2000). Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci U S A 97, 11250-11255.
Li, M., Brooks, C. L., Kon, N., and Gu, W. (2004). A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 13, 879-886.
Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., and Gu, W. (2003). Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302, 1972-1975.
Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J., and Gu, W. (2002).Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416, 648-653.
Liang, S. H., and Clarke, M. F. (2001). Regulation of p53 localization. Eur J Biochem 268, 2779-2783.
Lim, S. K., Shin, J. M., Kim, Y. S., and Baek, K. H. (2004). Identification and characterization of murine mHAUSP encoding a deubiquitinating enzyme that regulates the status of p53 ubiquitination. Int J Oncol 24, 357-364.
Lima, C. D. (2003). Regulating UBP-mediated ubiquitin deconjugation. Structure (Camb) 11, 3-4.
Lin, J., Chen, J., Elenbaas, B., and Levine, A. J. (1994). Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 8, 1235-1246.
Linke, S. P., Clarkin, K. C., Di Leonardo, A., Tsou, A., and Wahl, G. M. (1996). A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 10, 934-947.
Linzer, D. I., and Levine, A. J. (1979). Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 43-52.
Liu, L., Scolnick, D. M., Trievel, R. C., Zhang, H. B., Marmorstein, R., Halazonetis, T. D., and Berger, S. L. (1999). p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 19, 1202-1209.
Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. (1992). Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70, 923-935.
Llanos, S., Clark, P. A., Rowe, J., and Peters, G. (2001). Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 3, 445-452.
Lohrum, M. A., Woods, D. B., Ludwig, R. L., Balint, E., and Vousden, K. H. (2001). C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 21, 8521-8532.
Lu, H., and Levine, A. J. (1995). Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A 92, 5154-5158.
Mai, S., Fluri, M., Siwarski, D., and Huppi, K. (1996). Genomic instability in MycER-activated Rat1A-MycER cells. Chromosome Res 4, 365-371.
Maki, C. G., Huibregtse, J. M., and Howley, P. M. (1996). In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 56, 2649-2654.
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Jr., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., and et al. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238.
Marston, N. J., Jenkins, J. R., and Vousden, K. H. (1995). Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene 10, 1709-1715.
Maya, R., Balass, M., Kim, S. T., Shkedy, D., Leal, J. F., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., et al. (2001). ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev 15, 1067-1077.
Mayo, L. D., and Donner, D. B. (2001). A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 98, 11598-11603.
McCurrach, M. E., Connor, T. M., Knudson, C. M., Korsmeyer, S. J., and Lowe, S. W. (1997). bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci U S A 94, 2345-2349.
McLure, K. G., and Lee, P. W. (1998). How p53 binds DNA as a tetramer. Embo J 17, 3342-3350.
Meek, D. W. (2002). p53 Induction: phosphorylation sites cooperate in regulating. Cancer Biol Ther 1, 284-286.
Meek, D. W., and Knippschild, U. (2003). Posttranslational modification of MDM2. Mol Cancer Res 1, 1017-1026.
Mendrysa, S. M., McElwee, M. K., Michalowski, J., O'Leary, K. A., Young, K. M., and Perry, M. E. (2003). mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23, 462-472.
Meulmeester, E., Frenk, R., Stad, R., de Graaf, P., Marine, J. C., Vousden, K. H., and Jochemsen, A. G. (2003). Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 23, 4929-4938.
Michael, D., and Oren, M. (2003). The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13, 49-58.
Middeler, G., Zerf, K., Jenovai, S., Thulig, A., Tschodrich-Rotter, M., Kubitscheck, U., and Peters, R. (1997). The tumor suppressor p53 is subject to both nuclear import and export, and both are fast, energy-dependent and lectin-inhibited. Oncogene 14, 1407-1417.
Migliorini, D., Danovi, D., Colombo, E., Carbone, R., Pelicci, P. G., and Marine, J. C. (2002a). Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. J Biol Chem 277, 7318-7323.
Migliorini, D., Denchi, E. L., Danovi, D., Jochemsen, A., Capillo, M., Gobbi, A., Helin, K., Pelicci, P. G., and Marine, J. C. (2002b). Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 22, 5527-5538.
Migliorini, D., Denchi, E. L., Danovi, D., Jochemsen, A., Capillo, M., Gobbi, A., Helin, K., Pelicci, P. G., and Marine, J. C. (2002c). Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 22, 5527-5538.
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., and Moll, U. M. (2003). p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11, 577-590.
Minn, A. J., Boise, L. H., and Thompson, C. B. (1996). Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev 10, 2621-2631.
Mirnezami, A. H., Campbell, S. J., Darley, M., Primrose, J. N., Johnson, P. W., and Blaydes, J. P. (2003). Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription. Curr Biol 13, 1234-1239.
Moll, U. M., LaQuaglia, M., Benard, J., and Riou, G. (1995). Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A 92, 4407-4411.
Moll, U. M., Ostermeyer, A. G., Haladay, R., Winkfield, B., Frazier, M., and Zambetti, G. (1996). Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol 16, 1126-1137.
Moll, U. M., Riou, G., and Levine, A. J. (1992). Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A 89, 7262-7266.
Moll, U. M., and Zaika, A. (2001). Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett 493, 65-69.
Momand, J., Jung, D., Wilczynski, S., and Niland, J. (1998). The MDM2 gene amplification database. Nucleic Acids Res 26, 3453-3459.
Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245.
Montes de Oca Luna, R., Wagner, D. S., and Lozano, G. (1995). Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206.
Morgan, W. F., Bodycote, J., Fero, M. L., Hahn, P. J., Kapp, L. N., Pantelias, G. E., and Painter, R. B. (1986). A cytogenetic investigation of DNA rereplication after hydroxyurea treatment: implications for gene amplification. Chromosoma 93, 191-196.
Muratani, M., and Tansey, W. P. (2003). How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 4, 192-201.
Nakamura, S., Roth, J. A., and Mukhopadhyay, T. (2000). Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol 20, 9391-9398.
Nikolaev, A. Y., Li, M., Puskas, N., Qin, J., and Gu, W. (2003). Parc: a cytoplasmic anchor for p53. Cell 112, 29-40.
Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., and Smith, J. R. (1994). Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211, 90-98.
O'Keefe, K., Li, H., and Zhang, Y. (2003). Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol Cell Biol 23, 6396-6405.
Offer, H., Wolkowicz, R., Matas, D., Blumenstein, S., Livneh, Z., and Rotter, V. (1999). Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett 450, 197-204.
Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T., Tanaka, K., Masuyama, N., and Gotoh, Y. (2002). Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 277, 21843-21850.
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas [see comments]. Nature 358, 80-83.
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860.
Ollmann, M., Young, L. M., Di Como, C. J., Karim, F., Belvin, M., Robertson, S., Whittaker, K., Demsky, M., Fisher, W. W., Buchman, A., et al. (2000). Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell 101, 91-101.
Oren, M., Maltzman, W., and Levine, A. J. (1981). Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1, 101-110.
Ostermeyer, A. G., Runko, E., Winkfield, B., Ahn, B., and Moll, U. M. (1996). Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc Natl Acad Sci U S A 93, 15190-15194.
Pan, Y., and Chen, J. (2003). MDM2 Promotes Ubiquitination and Degradation of MDMX. Mol Cell Biol 23, 5113-5121.
Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., and Lozano, G. (2001). Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29, 92-95.
Perry, M. E., Commane, M., and Stark, G. R. (1992). Simian virus 40 large tumor antigen alone or two cooperating oncogenes convert REF52 cells to a state permissive for gene amplification. Proc Natl Acad Sci U S A 89, 8112-8116.
Perry, M. E., Piette, J., Zawadzki, J. A., Harvey, D., and Levine, A. J. (1993). The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci U S A 90, 11623-11627.
Peters, M., DeLuca, C., Hirao, A., Stambolic, V., Potter, J., Zhou, L., Liepa, J., Snow, B., Arya, S., Wong, J., et al. (2002). Chk2 regulates irradiation-induced, p53-mediated apoptosis in Drosophila. Proc Natl Acad Sci U S A 99, 11305-11310.
Poyurovsky, M. V., Jacq, X., Ma, C., Karni-Schmidt, O., Parker, P. J., Chalfie, M., Manley, J. L., and Prives, C. (2003). Nucleotide binding by the Mdm2 RING domain facilitates Arfindependent Mdm2 nucleolar localization. Mol Cell 12, 875-887.
Qu, L., Huang, S., Baltzis, D., Rivas-Estilla, A. M., Pluquet, O., Hatzoglou, M., Koumenis, C., Taya, Y., Yoshimura, A., and Koromilas, A. E. (2004). Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev 18, 261-277.
Riemenschneider, M. J., Buschges, R., Wolter, M., Reifenberger, J., Bostrom, J., Kraus, J. A., Schlegel, U., and Reifenberger, G. (1999). Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 59, 6091-6096.
Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M., and McCormick, F. (2000). Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103, 321-330.
Rodriguez, M. S., Desterro, J. M., Lain, S., Lane, D. P., and Hay, R. T. (2000). Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome- mediated degradation. Mol Cell Biol 20, 8458-8467.
Roth, J., Dobbelstein, M., Freedman, D. A., Shenk, T., and Levine, A. J. (1998). Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. Embo J 17, 554-564.
Rubbi, C. P., and Milner, J. (2003). Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. Embo J 22, 6068-6077.
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., and Appella, E. (1998). DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12, 2831-2841.
Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C. W., and Appella, E. (2000). Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J Biol Chem 275, 9278-9283.
Sakaguchi, K., Sakamoto, H., Lewis, M. S., Anderson, C. W., Erickson, J. W., Appella, E., and Xie, D. (1997). Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 36, 10117-10124.
Salghetti, S. E., Muratani, M., Wijnen, H., Futcher, B., and Tansey, W. P. (2000). Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc Natl Acad Sci U S A 97, 3118-3123.
Scheffner, M., Huibregtse, J. M., Vierstra, R. D., and Howley, P. M. (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505.
Schon, O., Friedler, A., Bycroft, M., Freund, S. M., and Fersht, A. R. (2002). Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol 323, 491-501.S
eo, Y. R., Fishel, M. L., Amundson, S., Kelley, M. R., and Smith, M. L. (2002). Implication of p53 in base excision DNA repair: in vivo evidence. Oncogene 21, 731-737.
Sharp, D. A., Kratowicz, S. A., Sank, M. J., and George, D. L. (1999). Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem 274, 38189-38196.
Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A., and Rotter, V. (1990). Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 10, 6565-6577.
Shaulsky, G., Goldfinger, N., Tosky, M. S., Levine, A. J., and Rotter, V. (1991). Nuclear localization is essential for the activity of p53 protein. Oncogene 6, 2055-2065.
Sherr, C. J. (2001). The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2, 731-737.
Shieh, S. Y., Ikeda, M., Taya, Y., and Prives, C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334.
Shieh, S. Y., Taya, Y., and Prives, C. (1999). DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J 18, 1815-1823.
Shirangi, T. R., Zaika, A., and Moll, U. M. (2002). Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage. FASEB J 16, 420-422.
Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., and Jochemsen, A. G. (1996). MDMX: a novel p53-binding protein with some functional properties of MDM2. Embo J 15, 5349-5357.
Siliciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E., and Kastan, M. B. (1997). DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11, 3471-3481.
Sluss, H. K., Armata, H., Gallant, J., and Jones, S. N. (2004). Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol Cell Biol 24, 976-984.
Smart, P., Lane, E. B., Lane, D. P., Midgley, C., Vojtesek, B., and Lain, S. (1999). Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 18, 7378-7386.
Smith, M. L., Ford, J. M., Hollander, M. C., Bortnick, R. A., Amundson, S. A., Seo, Y. R., Deng, C. X., Hanawalt, P. C., and Fornace, A. J., Jr. (2000). p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. Mol Cell Biol 20, 3705-3714.
Srivastava, S., Zou, Z. Q., Pirollo, K., Blattner, W., and Chang, E. H. (1990). Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348, 747-749.
Stad, R., Little, N. A., Xirodimas, D. P., Frenk, R., van der Eb, A. J., Lane, D. P., Saville, M. K., and Jochemsen, A. G. (2001). Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep 2, 1029-1034.
Stewart, Z. A., andPietenpol, J. A.(2001). p53 Signaling and cell cycle checkpoints. Chem Res Toxicol 14, 243-263.
Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., and Wahl, G. M. (1999). A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 18, 1660-1672.
Stommel, J. M., and Wahl, G. M. (2004). Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. Embo J 23, 1547-1556.
Sun, X. F., Carstensen, J. M., Zhang, H., Stal, O., Wingren, S., Hatschek, T., and Nordenskjold, B. (1992). Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340, 1369-1373.
Szak, S. T., Mays, D., and Pietenpol, J. A. (2001). Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol 21, 3375-3386.
Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., and Ohtsubo, M. (1999). MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 447, 5-9.
Tao, W., and Levine, A. J. (1999). Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2- mediated degradation of p53. Proc Natl Acad Sci U S A 96, 3077-3080.
Tergaonkar, V., Pando, M., Vafa, O., Wahl, G., and Verma, I. (2002). p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 1, 493-503.
Thrower, J. S., Hoffman, L., Rechsteiner, M., and Pickart, C. M. (2000). Recognition of the polyubiquitin proteolytic signal. Embo J 19, 94-102.
Thut, C. J., Chen, J. L., Klemm, R., and Tjian, R. (1995). p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267, 100-104.
Thut, C. J., Goodrich, J. A., and Tjian, R. (1997). Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 11, 1974-1986.
Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S. Y., Taya, Y., Prives, C., and Abraham, R. T. (1999). A role for ATR in the DNA damageinduced phosphorylation of p53. Genes Dev 13, 152-157.
Tolbert, D., Lu, X., Yin, C., Tantama, M., and Van Dyke, T. (2002). p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo. Mol Cell Biol 22, 370-377.
Unger, T., Juven-Gershon, T., Moallem, E., Berger, M., Vogt Sionov, R., Lozano, G., Oren, M., and Haupt, Y. (1999a). Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. Embo J 18, 1805-1814.
Unger, T., Sionov, R. V., Moallem, E., Yee, C. L., Howley, P. M., Oren, M., and Haupt, Y. (1999b). Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene 18, 3205-3212.
Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T. K., Hampton, G. M., and Wahl, G. M. (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9, 1031-1044.
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004). In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. Science 303, 844-848.
Villunger, A., Michalak, E. M., Coultas, L., Mullauer, F., Bock, G., Ausserlechner, M. J., Adams, J. M., and Strasser, A. (2003). p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302, 1036-1038.
Voorhoeve, P. M., and Agami, R. (2004). Unraveling Human Tumor Suppressor Pathways: A Tale of the INK4A Locus. Cell Cycle 3.
Wahl, G. M., and Carr, A. M. (2001). The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 3, E277-286.
Wahl, G. M., Linke, S. P., Paulson, T. G., and Huang, L. C. (1997). Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv 29, 183-219.
Wahl, G. M., Padgett, R. A., and Stark, G. R. (1979). Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells. J Biol Chem 254, 8679-8689.
Waldman, T., Kinzler, K. W., and Vogelstein, B. (1995). p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55, 5187-5190.
Wang, X., Taplick, J., Geva, N., and Oren, M. (2004). Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett 561, 195-201.
Watanabe, M., Fukuda, M., Yoshida, M., Yanagida, M., and Nishida, E. (1999). Involvement of CRM1, a nuclear export receptor, in mRNA export in mammalian cells and fission yeast. Genes Cells 4, 291-297.
Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., and Bar-Sagi, D. (1999). Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1, 20-26.
Windle, B., Draper, B. W., Yin, Y. X., O'Gorman, S., and Wahl, G. M. (1991). A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration. Genes Dev 5, 160-174.
Wolff, B., Sanglier, J. J., and Wang, Y. (1997). Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol 4, 139-147.
Wood, S. A. (2002). Dubble or nothing? Is HAUSP deubiquitylating enzyme the final arbiter of p53 levels? Sci STKE 2002, PE34.
Wouters, B. G., Giaccia, A. J., Denko, N. C., and Brown, J. M. (1997). Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res 57, 4703-4706.
Wu, X., Bayle, J. H., Olson, D., and Levine, A. J. (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7, 1126-1132.
Wu, Z., Earle, J., Saito, S., Anderson, C. W., Appella, E., and Xu, Y. (2002). Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol 22, 2441-2449.
Xiao, H., Pearson, A., Coulombe, B., Truant, R., Zhang, S., Regier, J. L., Triezenberg, S. J., Reinberg, D., Flores, O., Ingles, C. J., and et al. (1994). Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol Cell Biol 14, 7013-7024.
Xirodimas, D. P., Stephen, C. W., and Lane, D. P. (2001). Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2- mediated degradation of p53. Exp Cell Res 270, 66-77.
Yang, Q., Manicone, A., Coursen, J. D., Linke, S. P., Nagashima, M., Forgues, M., and Wang, X. W. (2000). Identification of a functional domain in a GADD45-mediated G2/M checkpoint. J Biol Chem 275, 36892-36898.
Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. (1992). Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70, 937-948.
Yoneda, Y., Imamoto-Sonobe, N., Yamaizumi, M., and Uchida, T. (1987). Reversible inhibition of protein import into the nucleus by wheat germ agglutinin injected into cultured cells. Exp Cell Res 173, 586-595.
Yu, Z. K., Geyer, R. K., and Maki, C. G. (2000). MDM2-dependent ubiquitination of nuclear and cytoplasmic p53. Oncogene 19, 5892-5897.
Zhang, Y., and Xiong, Y. (2001). A p53 amino-terminal nuclear export signal inhibited by DNA damage- induced phosphorylation. Science 292, 1910-1915.
Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., and Hung, M. C. (2001a). HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3, 973-982.
Zhou, J., Ahn, J., Wilson, S. H., and Prives, C. (2001b). A role for p53 in base excision repair. Embo J 20, 914-923.
Zhu, Q., Wani, G., Wani, M. A., and Wani, A. A. (2001a). Human homologue of yeast Rad23 protein A interacts with p300/cyclic AMP-responsive element binding (CREB)-binding protein to down-regulate transcriptional activity of p53. Cancer Res 61, 64-70.
Zhu, Q., Yao, J., Wani, G., Wani, M. A., and Wani, A. A. (2001b). Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53: Evidence for the role of p300 in integrating ubiquitination and proteolysis. J Biol Chem 4, 4.
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., and Roussel, M. F. (1998). Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12, 2424-2433.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer
About this chapter
Cite this chapter
Wahl, G.M., Stommel, J.M., Krummel, K., Wade, M. (2007). Gatekeepers of the Guardian: p53 Regulation by Post-Translational Modification, MDM2 and MDMX. In: Hainaut, P., Wiman, K.G. (eds) 25 Years of p53 Research. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-2922-6_4
Download citation
DOI: https://doi.org/10.1007/978-1-4020-2922-6_4
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-2920-2
Online ISBN: 978-1-4020-2922-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)